Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137558 | 1.00 | CA2 (0.34) | CA2 | |
| SCHEMBL1057409 | 1.00 | CA2 (0.34) | CA2 | |
| SCHEMBL31682138 | 0.98 | CA2 (0.33) | CA2 | |
| SCHEMBL31682159 | 0.98 | CA2 (0.33) | CA2 | |
| SCHEMBL9794171 | 0.98 | CA2 (0.33) | CA2 | |
| SCHEMBL31682129 | 0.98 | CA2 (0.33) | CA2 | |
| SCHEMBL9794153 | 0.98 | CA2 (0.33) | CA2 | |
| SCHEMBL9794169 | 0.98 | CA2 (0.33) | CA2 | |
| SCHEMBL9794156 | 0.98 | CA2 (0.33) | CA2 | |
| SCHEMBL9794085 | 0.98 | CA2 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166918-B1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY- CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | SCINOPHARM TAIWAN LTD (TW) | 2019-02-20 | — | — | EP | disclosed |
| US-9670234-B2 | Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy-cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs | SCINOPHARM TAIWAN, LTD. (TW) | 2017-06-06 | — | — | US | disclosed |
| EP-2864308-B1 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | UNIV BRISTOL (GB) | 2016-10-19 | — | — | EP | disclosed |
| EP-2864308-B1 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | UNIV BRISTOL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20160009740-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | SCINOPHARM TAIWAN, LTD. (TW) | 2016-01-14 | — | — | US | disclosed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| EP-0196617-B1 | [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same | SYNTEX (U.S.A.) INC. (US) | 1989-05-31 | — | — | EP | disclosed |
| US-4735966-A | ANTICOAGULANTS, VASODILATORS, HYPOTENSIVE AND ANTICHOLESTEROL AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-04-05 | — | — | US | disclosed |
| EP-0257609-A2 | Novel substituted (4.2.0)Bicyclooctane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1988-03-02 | — | — | EP | disclosed |
| EP-0255098-A1 | Novel 8-(lower alkyl) bicyclo [4.2.0] octane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1988-02-03 | — | — | EP | disclosed |
| US-4678805-A | Novel 8-(lower alkyl)bicyclo[4.2.0]octane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1987-07-07 | — | — | US | disclosed |
| EP-0196617-A1 | [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same | SYNTEX (U.S.A.) INC. (US) | 1986-10-08 | — | — | EP | disclosed |
| US-4608388-A | Novel [4,2,0]bicyclooctane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1986-08-26 | — | — | US | disclosed |
| EP-0100900-B1 | NOVEL (3.2.0.) BICYCLOHEPTANONE OXIME ETHERS WITH VALUABLE THERAPEUTIC PROPERTIES | SYNTEX (U.S.A.) INC. (US) | 1986-02-05 | — | — | EP | disclosed |
| US-4552898-A | CARDIOVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-11-12 | — | — | US | disclosed |
| EP-0100900-A1 | Novel (3.2.0.) bicycloheptanone oxime ethers with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009740-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | PTGIS, PTGER1, PTGS1 | CA2 419/4885 |
| US-20150158837-A1 | Compound And Method | CYP4A11, NR1H2, NR1H3 | CA2 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.